Consolidated Statements Of Operations (USD $)	3 Months Ended				9 Months Ended				65 Months Ended
	Sep. 30, 2012		Sep. 30, 2011		Sep. 30, 2012		Sep. 30, 2011		Sep. 30, 2012
Revenue
Operating expense
General & administrative	246,086	[1]	327,380	[1]	729,569	[1]	1,002,191	[1]	6,802,934	[1]
Total operating expense	840,489		504,489		2,150,898		1,560,994		12,016,899
Net operating loss	(840,489)		(504,489)		(2,150,898)		(1,560,994)		(12,016,899)
Other income
Interest income	26		870		768		2,171		77,079
Other income									244,479
Other expense	(89)		(200)		(487)		(471)		(4,023)
Total Other Income	(63)		670		281		1,700		317,535
Net Loss	(840,552)		(503,819)		(2,150,617)		(1,559,294)		(11,699,364)
Loss per share
Net loss per share, basic and diluted	$ (0.01)		$ (0.01)		$ (0.04)		$ (0.03)		$ (0.26)
Basic and diluted weighted average number of common shares outstanding	58,902,046		56,146,296		58,717,393		52,398,690		45,349,410
All Other
Operating expense
Research and Development	546,821	[2]	127,109	[2]	994,459	[2]	458,803	[2]	4,187,345	[2]
MD Anderson for License
Operating expense
Research and Development	$ 47,582	[3]	$ 50,000	[3]	$ 426,870	[3]	$ 100,000	[3]	$ 1,026,620	[3]

[1] General & administrative expense includes stock for services, stock option and warrant expenses of $105,491 for the quarter ending 9/30/2011; $21,750 and $314,869 for the nine month periods ending 9/30/2012 and 9/30/2011, respectively; and for the period from inception through 9/30/2012 $2,584,265 for stock option and warrant expense and $318,500 in stock for services.

[2] Research and development expense includes stock option expenses of $11,414 and $17,406 for the quarters ending 9/30/2012 and 9/30/2011, respectively; $42,231 and $48,693 for the nine month periods ending 9/30/2012 and 9/30/2011, respectively; and $411,585 for the period from inception through 9/30/2012. Research and development expense also includes amortization expenses of $48,503 and $53,017 for the quarters ending 9/30/2012 and 9/30/2011, respectively; $145,115 and $157,490 for the nine month periods ending 9/30/2012 and 9/30/2011, respectively; and $936,578 for the period from inception through 9/30/2012.

[3] Includes $345,000 technology impairment charge for the nine month period ending 9/30/2012; and $690,000 for the period from inception through 9/30/2012